About
Bio
Established in January 1993 and written for an international audience of senior company managers and members of the finance community. Supplies answers to important questions about corporate strategy, management decisions, partnering, emerging technology, clinical data and the financing markets that are key to understanding how value is created by biotechnology companies.
Departments and sections include: Cover Story, Marketing, Strategy, Technology, Noteworthy, Emerging Company Profile, Regulation, Politics and Policy, Ebb and Flow, Online this week, Stock charts and tables and Company index. The newsletter notes the featured Online Links of the week, where subscribers can be informed of news that is available on the web. Has three main sections: the A section BioCentury, The Bernstein Report on BioBusiness, which provides analysis, interpretation and commentary on industry development, corporate performance, technology, public policy and shareholder value; and BioCentury II, which is a compendium of corporate, clinical and financial news, providing an efficient surveillance of deals, regulatory events, clinical reports and financing activity.
This outlet offers RSS (Really Simple Syndication).
Email
email@cision.one
Website
site@cision.one
Social media
Location
United States of America
Frequency
upgrade
Circulation
upgrade
Sectors
Biotechnology, Biotechnology Industry
Bio
Established in January 1993 and written for an international audience of senior company managers and members of the finance community. Supplies answers to important questions about corporate strategy, management decisions, partnering, emerging technology, clinical data and the financing markets that are key to understanding how value is created by biotechnology companies. Departments and sections include: Cover Story, Marketing, Strategy, Technology, Noteworthy, Emerging Company Profile, Regulation, Politics and Policy, Ebb and Flow, Online this week, Stock charts and tables and Company index. The newsletter notes the featured Online Links of the week, where subscribers can be informed of news that is available on the web. Has three main sections: the A section BioCentury, The Bernstein Report on BioBusiness, which provides analysis, interpretation and commentary on industry development, corporate performance, technology, public policy and shareholder value; and BioCentury II, which is a compendium of corporate, clinical and financial news, providing an efficient surveillance of deals, regulatory events, clinical reports and financing activity. This outlet offers RSS (Really Simple Syndication).
Website
Social media
Location
Frequency
Circulation
Sectors
Biotechnology, Biotechnology Industry
Most recent articles by BioCentury Extra
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Article description
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Article description
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Article description
Explore outlets similar to BioCentury Extra
-
SScientific American
Established in 1845, Scientific American remains the oldest continuously-published magazine in the United States. Redesigned in October 2010, the publication covers the most important and exciting research in science, health, technology, the environment, and society, exploring important ideas often months and years before other media recognizes their importance. The magazine publishes 15 foreign language editions, and regular sections include Forum, which provides a platform for external experts to comment on science policy; Science Agenda, where editors can discuss different science issues; and Insights, which profiles a scientist or researcher and analyzes their contribution to society. Other sections include Anti Gravity and Skeptic. Regular columns include The Science of Health and TechnoFiles. Publicists should feel free to pitch anytime, although they should avoid pitching individual products or new company officer announcements. They should focus on science-based stories that are better told by a journalist than an expert.
ViewMMIT Technology ReviewEstablished in 1899 and written for venture capitalists and hi-tech executives as an informational source on innovative and improved technologies and their applications. Focuses on promoting the understanding of emerging technologies and their impact. Strives to promote the understanding of emerging technology and its impact on the world. Aims to promote the understanding of emerging technologies and to analyze their commercial, social and political impacts. Assists technology and business leaders including CXOs, entrepreneurs, researchers, venture capitalists and financiers as they drive the global economy.
ViewEEndpoints NewsEndpoints News covers Biopharmaceutical industry. Offers data-driven news and analysis for industry professionals covering research and development. Content is a combination of originally produced and curated from around the web and is available in real-time and via a daily newsletter. This site is available via RSS (Really Simple Syndication).
ViewPPink Sheet - CitelinePink Sheet is a website delivering insights and lessons learned that biopharma leaders need to inform their decision making and strategic planning from a policy and regulatory perspective, keep themselves and their companies out of trouble and in compliance, and get their products approved. More than just news, Pink Sheet provides analysis, and commentary focused on regulatory implications, including high value perspectives from insiders and thought leaders across the globe – giving regulatory professionals an objective view of how to anticipate challenges, minimize risks, and maximize opportunities. From lessons learned, to why today’s headlines matter; from trends shaping the dynamics of the global pharmaceutical and biotech sectors; to the exclusive, proprietary data behind these trends and more.
ViewNNature Reviews Drug DiscoveryImpact Factor:22.66 (Source: Scimago Journal & Country Rank)Circulation: The figure is not currently disclosed.Aims of the journal:Nature Reviews Drug Discovery is a monthly journal aimed at everyone working in the drug discovery and development arena. In addition it seeks to provide the highest-quality reviews and perspectives covering the entire field, each issue includes news stories that investigate the hottest topics in drug discovery, timely summaries of key primary research papers and concise updates on the latest advances in fast-moving areas such as new drug approvals, patent law and emerging industry trends.Content: The journal covers the following subjects: Target discovery Rational drug design Combinatorial and parallel synthesis Medicinal chemistry Key compound classes Natural products High-throughput screening Novel therapeutic approaches to disease states Microarrays Bioinformatics and chemoinformatics Absorption, distribution, metabolism and elimination (ADME) Pharmacokinetics and pharmacodynamics Pharmacology Toxicology Pharmacogenomics and toxicogenomics Drug delivery Biopharmaceuticals Biotechnology Vaccines Clinical trial evaluation Regulatory issues PharmacoeconomicsEditorial contacts: See the list of editors here.The editorial office can be reached at naturereviews@nature.com.Manuscript submission:To be published in nature Reviews Drug Discovery a manuscript should meet the following criteria: Timely, accurate and balanced Important to scientists in the specific field Interesting and accessible to researchers in other areas of Drug DiscoverySubmit online at http://mts-nrdd.nature.com/cgi-bin/main.plex
ViewUse CisionOne to find more relevant outletsExplore journalists that write for BioCentury Extra
-
E
-
J
Contact us to find more relevant journalistsContact BioCentury Extra and get access to over 850K accurate, up-to-date media profiles.
Discover the stories that impact your brand. In realtime.
CisionOne delivers relevant news, trends and conversations that matter to your brand with the world’s most comprehensive media monitoring service across Print, Online, TV, Radio, Social, Magazines, Podcasts and more.